Correlation between COVID-19 vaccination and diabetes mellitus: A systematic review

BACKGROUND Coronavirus disease 2019 (COVID-19) is one of the current global public health threats and vaccination is the most effective tool to reduce the spread and decrease the severity of COVID-19. Diabetes is one of the important chronic diseases threatening human health and is a common comorbidity of COVID-19. What is the impact of diabetes on the immunization effect of COVID-19 vaccination? Conversely, does vaccination against COVID-19 exacerbate the severity of pre-existing diseases in patients with diabetes? There are limited and conflicting data on the interrelationship between diabetes and COVID-19 vaccination. AIM To explore the clinical factors and possible mechanisms underlying the interaction between COVID-19 vaccination and diabetes. METHODS We conducted a comprehensive search of PubMed, MEDLINE, EMBASE, and Reference Citation Analysis (https://www.referencecitationanalysis.com) online databases, and medRxiv and bioRxiv gray literature using the keywords "SARS-CoV-2", "COVID-19", "vaccine", "vaccination", "antibody", and "diabetes" individually or in combination, with a cut-off date of December 2, 2022. We followed inclusion and exclusion criteria and after excluding duplicate publications, studies with quantifiable evidence were included in the full-text review, plus three manually searched publications, resulting in 54 studies being included in this review. RESULTS A total of 54 studies were included, from 17 countries. There were no randomized controlled studies. The largest sample size was 350963. The youngest of the included samples was 5 years old and the oldest was 98 years old. The included population included the general population and also some special populations with pediatric diabetes, hemodialysis, solid organ transplantation, and autoimmune diseases. The earliest study began in November 2020. Thirty studies discussed the effect of diabetes on vaccination, with the majority indicating that diabetes reduces the response to COVID-19 vaccination. The other 24 studies were on the effect of vaccination on diabetes, which included 18 case reports/series. Most of the studies concluded that COVID-19 vaccination had a risk of causing elevated blood glucose. A total of 12 of the 54 included studies indicated a "no effect" relationship between diabetes and vaccination. CONCLUSION There is a complex relationship between vaccination and diabetes with a bidirectional effect. Vaccination may contribute to the risk of worsening blood glucose in diabetic patients and diabetic patients may have a lower antibody response after vaccination than the general population.

[1]  T. Ali,et al.  Comparison of the safety and immunogenicity of the BNT-162b2 vaccine and the ChAdOx1 vaccine for solid organ transplant recipients: a prospective study , 2022, BMC Infectious Diseases.

[2]  G. Onder,et al.  Diabetes Affects Antibody Response to SARS-CoV-2 Vaccination in Older Residents of Long-Term Care Facilities: Data From the GeroCovid Vax Study. , 2022, Diabetes care.

[3]  L. Supino-Rosin,et al.  SARS-CoV-2 spike IgG titres up to 137 days following Comirnaty mRNA COVID-19 vaccination, Israel, February to May 2021 , 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[4]  A. Christoforidis,et al.  The impact of COVID-19 vaccination on glycaemic control in children and adolescents with type 1 diabetes mellitus on continuous glucose monitoring , 2022, Acta Diabetologica.

[5]  S. Acharya,et al.  COVID-19 Vaccine-Induced Rapid Progression of Prediabetes to Ketosis-Prone Diabetes Mellitus in an Elderly Male , 2022, Cureus.

[6]  G. H. Ryu,et al.  Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test , 2022, Diagnostics.

[7]  M. Cesur,et al.  Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination , 2022, Endocrine.

[8]  J. D. Santotoribio,et al.  Clinical Evaluation of Serum Levels of SARS-CoV-2 Anti-Spike Protein IgG Antibodies in Infected Patients and Vaccinated Subjects. , 2022, Clinical laboratory.

[9]  P. Shenoy,et al.  Effectiveness of delayed second dose of AZD1222 vaccine in patients with autoimmune rheumatic disease , 2022, Clinical Rheumatology.

[10]  Liming Li,et al.  Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus , 2022, Vaccines.

[11]  Bothamai Dechates,et al.  Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine , 2022, Diabetology International.

[12]  N. Ohmagari,et al.  Association of Impaired Fasting Glucose and Diabetes with SARS-CoV-2 Spike Antibody Titers after the BNT162b2 Vaccine among Health Care Workers in a Tertiary Hospital in Japan , 2022, Vaccines.

[13]  D. Chartoumpekis,et al.  Factors associated with anti-SARS-CoV-2 antibody titres 3 months post-vaccination with the second dose of BNT162b2 vaccine: a longitudinal observational cohort study in western Greece , 2022, BMJ Open.

[14]  H. Katagiri,et al.  Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan , 2022, Emerging infectious diseases.

[15]  R. McGregor,et al.  Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults , 2022, Vaccine.

[16]  M. Rocchi,et al.  Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination , 2022, Vaccines.

[17]  Takaaki Kobayashi,et al.  A Case Series of Ketoacidosis After Coronavirus Disease 2019 Vaccination in Patients With Type 1 Diabetes , 2022, Frontiers in Endocrinology.

[18]  A. Hatzakis,et al.  Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study , 2022, Vaccines.

[19]  Kanako Sakurai,et al.  Type 1 diabetes mellitus following COVID‐19 RNA‐based vaccine , 2022, Journal of diabetes investigation.

[20]  M. Emoto,et al.  New‐onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination: A case report , 2022, Journal of Diabetes Investigation.

[21]  B. Piccini,et al.  COVID‐19 vaccination in adolescents and young adults with type 1 diabetes: Glycemic control and side effects , 2022, Pediatric diabetes.

[22]  M. Emoto,et al.  New-onset Type 1 Diabetes after COVID-19 mRNA Vaccination , 2022, Internal medicine.

[23]  A. Singh,et al.  Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study , 2022, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[24]  K. Soonklang,et al.  Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population , 2022, Human vaccines & immunotherapeutics.

[25]  H. Itoh,et al.  Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report , 2022, Journal of diabetes investigation.

[26]  T. Fujimura,et al.  Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy , 2022, The Journal of dermatology.

[27]  J. M. Gibson,et al.  The change in glycaemic control immediately after COVID‐19 vaccination in people with type 1 diabetes , 2021, Diabetic medicine : a journal of the British Diabetic Association.

[28]  J. Naschitz,et al.  Comparison of Covid-19 antibody status after vaccination between residents in long-term geriatric care and residents assisted-living facilities , 2021, Infectious diseases.

[29]  S. Heymans,et al.  Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms , 2021, Nature Reviews Cardiology.

[30]  A. Ellebedy,et al.  The germinal centre B cell response to SARS-CoV-2 , 2021, Nature reviews. Immunology.

[31]  V. Libri,et al.  Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial , 2021, The Lancet.

[32]  Madhukar Mittal,et al.  Diabetic ketoacidosis (DKA) in type 1 diabetes mellitus (T1DM) temporally related to COVID-19 vaccination , 2021, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[33]  B. Duncan,et al.  IDF diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 , 2021, Diabetes Research and Clinical Practice.

[34]  H. Sourij,et al.  Impact of COVID-19 Vaccination on Glycemia in Individuals With Type 1 and Type 2 Diabetes: Substudy of the COVAC-DM Study. , 2021, Diabetes care.

[35]  N. Goswami,et al.  Humoral immune response to COVID‐19 vaccination in diabetes is age‐dependent but independent of type of diabetes and glycaemic control: The prospective COVAC‐DM cohort study , 2021, medRxiv.

[36]  A. Antonelli,et al.  A case of Graves' disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination , 2021, Journal of Autoimmunity.

[37]  E. Güzel,et al.  Immunogenicity after CoronaVac vaccination , 2021, Revista da Associação Médica Brasileira.

[38]  J. Sohn,et al.  Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2 , 2021, Frontiers in Medicine.

[39]  Y. Tomer,et al.  Hyperglycemic Emergencies Associated With COVID-19 Vaccination: A Case Series and Discussion , 2021, Journal of the Endocrine Society.

[40]  A. Singh,et al.  Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study , 2021, Vaccine.

[41]  A. Demidowich,et al.  Severe Diabetic Ketoacidosis After the Second Dose of mRNA-1273 COVID-19 Vaccine , 2021, Journal of diabetes science and technology.

[42]  G. Paolisso,et al.  Does poor glycaemic control affect the immunogenicity of the COVID‐19 vaccination in patients with type 2 diabetes: The CAVEAT study , 2021, Diabetes, obesity & metabolism.

[43]  Nguyen H. Tran,et al.  Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) , 2021, The Lancet.

[44]  Karamese Murat,et al.  The Effectiveness of Inactivated SARS-CoV-2 Vaccine (CoronaVac) on Antibody Response in Participants Aged 65 Years and Older. , 2021, Journal of medical virology.

[45]  R. Buzzetti,et al.  Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes , 2021, Diabetes Research and Clinical Practice.

[46]  E. Woo,et al.  Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[47]  A. Kaneda,et al.  Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan , 2021, Clinical Microbiology and Infection.

[48]  M. Dimopoulos,et al.  Early and late endocrine complications of COVID-19 , 2021, Endocrine connections.

[49]  M. Abu-Farha,et al.  Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination , 2021, Frontiers in Immunology.

[50]  J. Klingström,et al.  Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination , 2021, The New England journal of medicine.

[51]  S. Valkenburg,et al.  Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID‐19 vaccines in Hong Kong , 2021, medRxiv.

[52]  J. Gargano,et al.  Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[53]  Frances E. Muldoon,et al.  Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 , 2021, Nature.

[54]  S. Finer,et al.  Acute hyperglycaemic crisis after vaccination against COVID‐19: A case series , 2021, Diabetic medicine : a journal of the British Diabetic Association.

[55]  S. Takeda,et al.  The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan , 2021, medRxiv.

[56]  Michael I. Mandel,et al.  Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel , 2021, Preventive Medicine.

[57]  M. Whyte,et al.  Analysis of continuous glucose tracking data in people with type 1 diabetes after COVID‐19 vaccination reveals unexpected link between immune and metabolic response, augmented by adjunctive oral medication , 2021, International journal of clinical practice.

[58]  S. Samuel,et al.  Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing , 2021, PLoS pathogens.

[59]  A. Jabłecka,et al.  Pancreatic Injury after COVID-19 Vaccine—A Case Report , 2021, Vaccines.

[60]  Gheyath K Nasrallah,et al.  Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses , 2021, Journal of travel medicine.

[61]  A. Mishra,et al.  Exacerbation of hyperglycemia in patients with type 2 diabetes after vaccination for COVID19: Report of three cases , 2021, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[62]  Ali I. Al-Gareeb,et al.  COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus , 2021, Frontiers in Cardiovascular Medicine.

[63]  Cynthia Lee,et al.  20 Post‐COVID‐19 vaccine‐related shingles cases seen at the Las Vegas Dermatology clinic and sent to us via social media , 2021, Journal of cosmetic dermatology.

[64]  N. Bishop,et al.  Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms , 2021, Kidney International.

[65]  D. Yahav,et al.  Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients - a prospective cohort study , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[66]  O. Parkash,et al.  Acute Pancreatitis: A Possible Side Effect of COVID-19 Vaccine , 2021, Cureus.

[67]  Jennifer H. Martin,et al.  Untimely Myocardial Infarction or COVID-19 Vaccine Side Effect , 2021, Cureus.

[68]  N. Gharaibeh,et al.  COVID-19 Vaccine and Hyperosmolar Hyperglycemic State , 2021, Cureus.

[69]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[70]  C. Norris,et al.  Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones , 2020, American journal of physiology. Heart and circulatory physiology.

[71]  K. Walker.  SARS-CoV-2 Vaccine , 2020, Global reproductive health.

[72]  Lu Zhang,et al.  mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection , 2020, International journal of molecular sciences.

[73]  Nguyen H. Tran,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.

[74]  S. Del Prato,et al.  COVID-19 in people with diabetes: understanding the reasons for worse outcomes , 2020, The Lancet Diabetes & Endocrinology.

[75]  Suheda Erener.  Diabetes, infection risk and COVID-19 , 2020, Molecular Metabolism.

[76]  M. Zheng,et al.  Patients with diabetes are at higher risk for severe illness from COVID-19 , 2020, Diabetes & Metabolism.

[77]  B. Gessner,et al.  Diabetes mellitus as a vaccine-effect modifier: a review , 2020, Expert review of vaccines.

[78]  C. Weyand,et al.  Influence of immune aging on vaccine responses , 2020, Journal of Allergy and Clinical Immunology.

[79]  Ritesh Gupta,et al.  Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[80]  R. Muniyappa,et al.  COVID-19 pandemic, coronaviruses, and diabetes mellitus , 2020, American journal of physiology. Endocrinology and metabolism.

[81]  Michael Roth,et al.  Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? , 2020, The Lancet Respiratory Medicine.

[82]  K. Kim,et al.  What Is COVID-19? , 2020, Frontiers for Young Minds.

[83]  G. Hitman,et al.  Type 2 diabetes is associated with the accumulation of senescent T cells , 2019, Clinical and experimental immunology.

[84]  C. Weyand,et al.  Mechanisms underlying T cell ageing , 2019, Nature Reviews Immunology.

[85]  G. Alter,et al.  Sex differences in vaccine-induced humoral immunity , 2018, Seminars in Immunopathology.

[86]  D. Cook,et al.  Risk of Infection in Type 1 and Type 2 Diabetes Compared With the General Population: A Matched Cohort Study , 2018, Diabetes Care.

[87]  M. Beck,et al.  Obesity Impairs the Adaptive Immune Response to Influenza Virus , 2017, Annals of the American Thoracic Society.

[88]  Prasenjit Manna,et al.  Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies. , 2015, Metabolic syndrome and related disorders.

[89]  Mark M. Davis,et al.  Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination , 2013, Proceedings of the National Academy of Sciences.

[90]  M. Beck,et al.  Micronutrients, immunology and inflammation The impact of obesity on the immune response to infection , 2016 .

[91]  N. Kalupahana,et al.  The renin‐angiotensin system: a link between obesity, inflammation and insulin resistance , 2012, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[92]  R. Koup,et al.  Analysis of Total Human Immunodeficiency Virus (HIV)-Specific CD4+ and CD8+ T-Cell Responses: Relationship to Viral Load in Untreated HIV Infection , 2001, Journal of Virology.

[93]  A. Alibrandi,et al.  Long term persistence of anti-HBs protective levels in young patients with type 1 diabetes after recombinant hepatitis B vaccine. , 2000, Vaccine.

[94]  S. Yaturu,et al.  COVID-19 Vaccine Related Hyperosmolar Hyperglycemic State and Normalized Glycemia within 2 Months , 2022, Journal of Diabetes Mellitus.